• Explore /
  • Poster
  • / Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).

Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).

Abstract Poster

Authors

null

Rosa Nadal

Laboratory of Transplantation Immunotherapy, Cellular and Molecular Therapeutics Branch, NHLBI, NIH, Bethesda, MD

Rosa Nadal , Stefan Barisic , Gina M. Scurti , Elena Cherkasova , Long Chen , Kristen Wood , Steven L. Highfill , Brian Wells , Georg Aue , Reem Shalabi , Thomas E. Hughes , Xin Tian , Yifei Xu , Ashkan A. Malayeri , Mohammadhadi H. Bagheri , Robert N. Reger , Michael I. Nishimura , Richard W. Childs

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Cellular Immmunotherapy

Clinical Trial Registration Number

NCT03354390

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 2549)

DOI

10.1200/JCO.2023.41.16_suppl.2549

Abstract #

2549

Poster Bd #

391

Abstract Disclosures

Similar Posters

First Author: Rosa Nadal

First Author: Rodabe Navroze Amaria

First Author: Christian S. Hinrichs

Poster

2024 ASCO Annual Meeting

<span>Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.</span>

Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.

First Author: Jiayong Liu